Verastem

VSTM · NASDAQ

$9.34+$0.72 (+8.35%)TodayMarket closed · Oct 20, 7:41 PM ET

Prev close $8.62

Latest news

NewsOct 14, 10:17 AM ETVandana Singh
Verastem Oncology's Investigational Drug Delivers Encouraging Responses Across Multiple Cancers
NewsOct 14, 10:02 AM ETAvi Kapoor
Bending Spoons, Liquidia, Verastem And Other Big Stocks Moving Higher On Wednesday
Press releaseOct 14, 6:04 AM ETBusiness Wire
Verastem Oncology Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants
Press releaseOct 14, 6:01 AM ETBusiness Wire
Verastem Oncology Announces Planned Chief Executive Officer Transition and Succession Plan
Press releaseOct 14, 6:00 AM ETBusiness Wire
VS-7375 Demonstrates Robust Anti-Tumor Activity Across Advanced KRAS G12D-Mutant Cancers, Highlighted by 50% Confirmed ORR in 2L Pancreatic Ductal Adenocarcinoma and Two Complete Responses in 2L+ Disease (One Confirmed)
NewsOct 12, 9:01 AM ET
Verastem Oncology Q2 2026 Earnings Call Transcript
Press releaseOct 5, 4:02 PM ETBusiness Wire
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releaseOct 2, 7:30 AM ETBusiness Wire
Verastem Oncology Announces New RAMP 201 Molecular Profiling and External Control Arm Analyses Describing Outcomes for Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at IGCS 2026
Press releaseSep 28, 4:10 PM ETBusiness Wire
Verastem Oncology Announces Publication in Gynecologic Oncology of Two-Year Median Follow-Up Data from RAMP 201 Study of AVMAPKI® FAKZYNJA® CO-PACK (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer
Press releaseSep 28, 8:00 AM ETPRNewswire
KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034
Press releaseSep 24, 8:30 AM ETBusiness Wire
Verastem Oncology Announces Late-Breaking Oral Presentation of RAMP 201 Low-Grade Serous Ovarian Cancer Molecular Profiling and Tumor Biomarker Analysis at IGCS 2026 Annual Global Meeting
Press releaseSep 8, 7:30 AM ETBusiness Wire
Verastem Oncology to Unveil New Clinical Data Highlighting the Best-in-Class Potential of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, Across Pancreatic, Lung, and Colorectal Cancers
Press releaseSep 2, 7:30 AM ETBusiness Wire
Verastem Oncology to Participate in Upcoming September Investor Conferences
Press releaseAug 6, 4:01 PM ETBusiness Wire
Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates
Press releaseJul 28, 4:01 PM ETBusiness Wire
Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer
NewsJul 23, 5:06 PM ET
12 Health Care Stocks Moving In Thursday's After-Market Session
Press releaseJul 23, 7:30 AM ETBusiness Wire
Verastem Oncology to Report Second Quarter 2026 Financial Results on August 6, 2026
Press releaseJul 22, 4:01 PM ETBusiness Wire
Verastem Oncology Doses First Patient in TARGET-D 202 Phase 2 Registration-Directed Trial of VS-7375 for KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer
NewsJul 21, 3:52 PM ETPiero Cingari
These 7 Small Caps Are on Fire as the Second Half Begins: Here’s Why
Press releaseJul 2, 4:30 PM ETBusiness Wire
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releaseJun 23, 4:01 PM ETBusiness Wire
VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors
NewsJun 17, 12:45 PM ETVandana Singh
Verastem Stock Jumps As Data Shows Strong Survival Trends In Pancreatic Cancer
Press releaseJun 17, 7:30 AM ETBusiness Wire
Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in First-Line Metastatic Pancreatic Cancer
Press releaseJun 16, 4:01 PM ETBusiness Wire
Verastem Oncology Doses First Patient in TARGET-D 201 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Pancreatic Cancer
Press releaseJun 15, 4:01 PM ETBusiness Wire
Verastem Oncology to Host Investor Conference Call and Report Updated Data and Progress Across VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor TARGET-D Clinical Program
Press releaseJun 3, 4:01 PM ETBusiness Wire
Verastem Oncology Announces U.S. FDA Fast Track Designation for VS-7375, an Oral and Potential Best-in-Class Investigational KRAS G12D (ON/OFF) Inhibitor for the Treatment of KRAS G12D-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Press releaseMay 27, 7:30 AM ETBusiness Wire
Verastem Oncology to Present at Jefferies Healthcare Conference
Press releaseMay 26, 7:30 AM ETBusiness Wire
Verastem Oncology Appoints Michael P. Bailey to its Board of Directors
Press releaseMay 12, 7:30 AM ETBusiness Wire
Verastem Oncology to Present at Upcoming Investor Conferences
Press releaseMay 8, 7:30 AM ETBusiness Wire
On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian Cancer
Press releaseMay 7, 4:01 PM ETBusiness Wire
Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
NewsMar 4, 4:07 PM ET
Earnings Summary: Verastem Q4
NewsMar 4, 6:11 AM ET
Earnings Scheduled For March 4, 2026
NewsMar 3, 12:03 PM ET
Earnings Outlook For Verastem
Press releaseFeb 4, 7:30 AM ETBusiness Wire
Verastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven Cancers
NewsDec 30, 12:54 AM ETAvi Kapoor
Verastem, TEN Holdings And 3 Stocks To Watch Heading Into Tuesday
NewsNov 14, 8:17 AM ETAvi Kapoor
Red Cat Posts Downbeat Q3 Results, Joins StubHub, WhiteFiber And Other Big Stocks Moving Lower In Friday's Pre-Market Session
NewsNov 14, 7:06 AM ET
12 Health Care Stocks Moving In Friday's Pre-Market Session

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Verastem Oncology's Investigational Drug Delivers Encouraging Responses Across Multiple Cancers

Bending Spoons, Liquidia, Verastem And Other Big Stocks Moving Higher On Wednesday

Verastem Oncology Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants

Verastem Oncology Announces Planned Chief Executive Officer Transition and Succession Plan

VS-7375 Demonstrates Robust Anti-Tumor Activity Across Advanced KRAS G12D-Mutant Cancers, Highlighted by 50% Confirmed ORR in 2L Pancreatic Ductal Adenocarcinoma and Two Complete Responses in 2L+ Disease (One Confirmed)

Verastem Oncology Q2 2026 Earnings Call Transcript

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem Oncology Announces New RAMP 201 Molecular Profiling and External Control Arm Analyses Describing Outcomes for Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at IGCS 2026

Verastem Oncology Announces Publication in Gynecologic Oncology of Two-Year Median Follow-Up Data from RAMP 201 Study of AVMAPKI® FAKZYNJA® CO-PACK (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer

KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034

Verastem Oncology Announces Late-Breaking Oral Presentation of RAMP 201 Low-Grade Serous Ovarian Cancer Molecular Profiling and Tumor Biomarker Analysis at IGCS 2026 Annual Global Meeting

Verastem Oncology to Unveil New Clinical Data Highlighting the Best-in-Class Potential of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, Across Pancreatic, Lung, and Colorectal Cancers

Verastem Oncology to Participate in Upcoming September Investor Conferences

Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer

12 Health Care Stocks Moving In Thursday's After-Market Session

Verastem Oncology to Report Second Quarter 2026 Financial Results on August 6, 2026

Verastem Oncology Doses First Patient in TARGET-D 202 Phase 2 Registration-Directed Trial of VS-7375 for KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer

These 7 Small Caps Are on Fire as the Second Half Begins: Here’s Why

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors

Verastem Stock Jumps As Data Shows Strong Survival Trends In Pancreatic Cancer

Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in First-Line Metastatic Pancreatic Cancer

Verastem Oncology Doses First Patient in TARGET-D 201 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Pancreatic Cancer

Verastem Oncology to Host Investor Conference Call and Report Updated Data and Progress Across VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor TARGET-D Clinical Program

Verastem Oncology Announces U.S. FDA Fast Track Designation for VS-7375, an Oral and Potential Best-in-Class Investigational KRAS G12D (ON/OFF) Inhibitor for the Treatment of KRAS G12D-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Verastem Oncology to Present at Jefferies Healthcare Conference

Verastem Oncology Appoints Michael P. Bailey to its Board of Directors

Verastem Oncology to Present at Upcoming Investor Conferences

On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian Cancer

Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates

Earnings Summary: Verastem Q4

Earnings Scheduled For March 4, 2026

Earnings Outlook For Verastem

Verastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven Cancers

Verastem, TEN Holdings And 3 Stocks To Watch Heading Into Tuesday

Red Cat Posts Downbeat Q3 Results, Joins StubHub, WhiteFiber And Other Big Stocks Moving Lower In Friday's Pre-Market Session

12 Health Care Stocks Moving In Friday's Pre-Market Session